SCHEMBL3670699

SCHEMBL3670699

O=C(c1cc(-c2ccc3[nH]ncc3c2)on1)N1CCOCC1c1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCD5 Q86SK9 10/20 0.66
ROCK2 O75116 5/20 0.59
CLK4 Q9HAZ1 4/20 0.59
STK17A Q9UEE5 3/20 0.59
DYRK1A Q13627 3/20 0.59
RPS6KB1 P23443 3/20 0.55
CLK2 P49760 3/20 0.55
ROCK1 Q13464 3/20 0.55
DYRK3 O43781 1/20 0.55
MKNK2 Q9HBH9 1/20 0.55
CSNK1G1 Q9HCP0 1/20 0.55
SCD O00767 9/20 0.52
GSK3B P49841 3/20 0.50
PIM1 P11309 2/20 0.50
AURKA O14965 2/20 0.50
DAPK3 O43293 2/20 0.50
JAK2 O60674 2/20 0.50
FGFR1 P11362 2/20 0.50
PRKACA P17612 2/20 0.50
KDR P35968 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3668422 0.87 SCD (0.70) SCD5ROCK2CLK4STK17ADYRK1A
SCHEMBL3673041 0.86 SCD (0.66) SCD5ROCK2CLK4STK17ADYRK1A
SCHEMBL3668953 0.85 ROCK2 (0.58) SCD5ROCK2CLK4STK17ADYRK1A
SCHEMBL21535922 0.80 SCD5 (1.00) SCD5SCD
SCHEMBL4287675 0.80 ROCK2 (0.82) ROCK2CLK4STK17ADYRK1ARPS6KB1
SCHEMBL3673647 0.78 ROCK2 (0.72) SCD5ROCK2CLK4STK17ADYRK1A
SCHEMBL3670619 0.75 ROCK2 (0.73) ROCK2CLK4STK17ADYRK1ARPS6KB1
SCHEMBL3666769 0.74 ROCK2 (1.00) ROCK2CLK4STK17ADYRK1ARPS6KB1
SCHEMBL3666006 0.73 ROCK2 (0.73) ROCK2CLK4STK17ADYRK1ARPS6KB1
SCHEMBL3670140 0.71 ROCK2 (1.00) SCD5ROCK2CLK4STK17ADYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP claimed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 SCD5 3059/4885ROCK2 48/4885CLK4 260/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 SCD5 3059/4885ROCK2 48/4885CLK4 260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.